Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Quidel Corporation
  6. Company
    QDEL   US74838J1016

QUIDEL CORPORATION

(QDEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Quidel Corporation
Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain.

Number of employees : 1 370 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Rapid Immunoassay191.7435.8%1,14568.9% +497.09%
Cardiac Immunoassay266.5149.8%242.9314.6% -8.84%
Molecular Diagnostic Solutions21.724.1%222.9613.4% +926.73%
Specialized Diagnostic Solutions54.9310.3%50.943.1% -7.27%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States358.3867%1,45287.4% +305.25%
Foreign176.5133%209.3412.6% +18.6%
Managers
NameAgeSinceTitle
Douglas Bryant622009President, Chief Executive Officer & Director
Randall Steward65-Chief Financial & Accounting Officer
Werner Kroll632014Senior Vice President-Research & Development
Karen Gibson572019SVP-Information Systems & Business Transformation
Robert Bujarski522020Chief Operating Officer
Mary Lake Polan, Dr.761993Independent Director
Kenneth Buechler662015Chairman
Kenneth J. Widder, Dr.672014Independent Director
Charles P. Slacik662015Independent Director
Matthew William Strobeck, Dr.472018Independent Director
Members of the board
NameAgeSinceTitle
Kenneth Buechler662015Chairman
Mary Lake Polan, Dr.761993Independent Director
Douglas Bryant622009President, Chief Executive Officer & Director
Kenneth J. Widder, Dr.672014Independent Director
Charles P. Slacik662015Independent Director
Matthew William Strobeck, Dr.472018Independent Director
Edward L. Michael632018Independent Director
Kathy P. Ordoñez692019Independent Director
Ann D. Rhoads552020Independent Director
Joseph D. Wilkins582021Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,550,816 37,471,830 88.1% 0 0.0% 88.1%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 6,425,323 15.1%
Jack Schuler 4,273,512 10.0%
The Vanguard Group, Inc. 3,721,128 8.75%
Brown Capital Management LLC 2,266,241 5.33%
Wellington Management Co. LLP 1,364,713 3.21%
Longwood Investment Advisors, Inc. 1,241,900 2.92%
BlackRock Fund Advisors 1,225,045 2.88%
Fred Alger Management LLC 1,189,424 2.80%
WHV Investments, Inc. 1,162,073 2.73%
Oracle Investment Management, Inc. 1,090,309 2.56%
Sector Other Advanced Medical Equipment & Technology